Literature DB >> 7767944

The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.

N Yamamoto1, T Tamura, M Maeda, M Ando, T Shinkai, K Eguchi, Y Ohe, F Oshita, J Shiraishi, N Katsumata.   

Abstract

This study was performed to identify any relationship between age and cisplatin (CDDP) pharmacokinetics in lung cancer patients. CDDP was given at a dose of 80 mg/m2 by 1-h intravenous infusion to 23 lung cancer patients. All patients had normal renal, hepatic, and bone marrow functions. We measured ultrafilterable platinum (U-Pt) and total plasma platinum (T-Pt) using atomic absorption spectrometry. There was significant correlation between the age of the patients and U-Pt pharmacokinetic parameters such as the area under the plasma concentration versus time curve (AUC), total clearance (Cl), and peak plasma concentration (Cmax) as well as the AUC of T-Pt (P < 0.05). We performed univariate regression analysis to examine the influence of factors aside from age on the AUC of U-Pt and T-Pt. Creatinine and GPT levels were significantly related to the AUC of U-Pt, and creatinine clearance and creatinine concentrations were significantly related to the AUC of T-Pt. Therefore, stepwise multiple-regression models for the AUC of U-Pt and T-Pt were developed to assess an age effect. Age was consistently an independent and significant predictor of the AUC of U-Pt and T-Pt.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767944     DOI: 10.1007/BF00689192

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

Review 1.  Aging and drug disposition: an update.

Authors:  D L Schmucker
Journal:  Pharmacol Rev       Date:  1985-06       Impact factor: 25.468

Review 2.  Pharmacokinetics in old age.

Authors:  B F Tregaskis; L H Stevenson
Journal:  Br Med Bull       Date:  1990-01       Impact factor: 4.291

3.  Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data.

Authors:  J M Borkowski; M Duerr; R C Donehower; E K Rowinsky; T L Chen; D S Ettinger; L B Grochow
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

6.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

7.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

Review 8.  The expanding role of cisplatin in the treatment of non-small-cell lung cancer.

Authors:  P A Bunn
Journal:  Semin Oncol       Date:  1989-08       Impact factor: 4.929

9.  Mechanism of cisplatin nephrotoxicity.

Authors:  M W Weiner; C Jacobs
Journal:  Fed Proc       Date:  1983-10

10.  Pharmacokinetic study of mitomycin C with emphasis on the influence of aging.

Authors:  T Miya; Y Sasaki; A Karato; N Saijo
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  9 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.

Authors:  T Miya; T Goya; H Fujii; T Ohtsu; K Itoh; T Igarashi; H Minami; Y Sasaki
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 3.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 4.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

5.  Urothelial carcinoma management in elderly or unfit patients.

Authors:  Joaquim Bellmunt; Nicolas Mottet; Maria De Santis
Journal:  EJC Suppl       Date:  2016-03-22

6.  Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.

Authors:  Marie-Rose B S Crombag; Markus Joerger; Beat Thürlimann; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancers (Basel)       Date:  2016-01-02       Impact factor: 6.639

7.  Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro.

Authors:  Y Shi; S Inoue; R Shinozaki; K Fukue; T Kougo
Journal:  Jpn J Cancer Res       Date:  1998-07

8.  Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions.

Authors:  F Oshita; T Kurata; T Kasai; M Fakuda; N Yamamoto; Y Ohe; T Tamura; K Eguchi; T Shinkai; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-12

Review 9.  Cisplatin-induced renal toxicity in elderly people.

Authors:  ZhiYu Duan; GuangYan Cai; JiJun Li; XiangMei Chen
Journal:  Ther Adv Med Oncol       Date:  2020-05-18       Impact factor: 8.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.